JNJ · XBRL financial data

Johnson & Johnson financial statements, every fiscal year

The same tables from 10 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (JNJ's year ends in late December)

In millions of dollars	FY 2020Jan 3, 2021	FY 2021Jan 2, 2022	FY 2022Jan 1, 2023	FY 2023Dec 31, 2023	FY 2024Dec 29, 2024	FY 2025Dec 28, 2025
Revenue from contracts with customers	82,584	93,775	94,943	85,159	88,821	94,193
Cost of goods and services sold	28,427	29,855	31,089	26,553	27,471	30,256
Gross profit	54,157	63,920	63,854	58,606	61,350	63,937
Research and development	—	0	0	483	1,841	109
Selling, general and administrative	22,084	24,659	24,765	21,512	22,869	23,676
Interest income	111	53	490	1,261	1,332	1,056
Interest expense	201	183	276	772	755	971
Other income (expense)	(2,899)	(489)	(1,871)	(6,634)	(4,694)	7,209
Income tax expense (benefit)	1,783	1,898	3,784	1,736	2,621	5,777
Net income (loss)	14,714	20,878	17,941	35,153	14,066	26,804
Earnings per share, basic USD per share	5.59	7.93	6.83	13.88	5.84	11.13
Earnings per share, diluted USD per share	5.51	7.81	6.73	13.72	5.79	11.03
Weighted average shares, basic millions of shares	2,633	2,632	2,625	2,534	2,407	2,407
Weighted average shares, diluted millions of shares	2,671	2,674	2,664	2,560	2,429	2,429

Fiscal years (JNJ's year ends in late December)

In millions of dollars	FY 2020Jan 3, 2021	FY 2021Jan 2, 2022	FY 2022Jan 1, 2023	FY 2023Dec 31, 2023	FY 2024Dec 29, 2024	FY 2025Dec 28, 2025
Cash and cash equivalents	13,985	14,487	14,127	21,859	24,105	19,709
Marketable securities	11,200	17,121	9,392	1,068	417	393
Accounts receivable	13,576	15,283	16,160	14,873	14,842	17,178
Inventory	9,344	10,387	12,483	11,181	12,444	14,191
Prepaid and other current assets	3,132	3,701	3,132	4,514	4,085	4,153
Total current assets	51,237	60,979	55,294	53,495	55,893	55,624
Property and equipment, net	18,766	18,962	19,803	19,898	20,518	23,169
Right-of-use asset	1,000	900	1,100	1,000	1,100	1,300
Goodwill	36,393	35,246	45,231	36,558	44,200	48,772
Total assets	174,894	182,018	187,378	167,558	180,104	199,210
Accounts payable	9,505	11,055	11,703	9,632	10,311	11,991
Accrued liabilities	13,968	13,612	11,456	10,212	8,549	8,594
Current portion of long-term debt	1,799	2,131	1,551	1,469	1,749	2,000
Total current liabilities	42,493	45,226	55,802	46,282	50,321	54,126
Long-term debt	32,635	29,985	26,888	25,881	30,651	39,438
Total liabilities	111,616	107,995	110,574	98,784	108,614	117,666
Retained earnings	113,890	123,060	128,345	153,843	155,791	168,978
Total stockholders' equity	—	—	76,804	68,774	71,490	81,544
Total liabilities and equity	174,894	182,018	187,378	167,558	180,104	199,210
Common shares outstanding (cover page) millions of shares	2,629	2,629	2,604	2,409	2,408	2,410

Fiscal years (JNJ's year ends in late December)

In millions of dollars	FY 2020Jan 3, 2021	FY 2021Jan 2, 2022	FY 2022Jan 1, 2023	FY 2023Dec 31, 2023	FY 2024Dec 29, 2024	FY 2025Dec 28, 2025
Net income (loss)	14,714	20,878	17,941	35,153	14,066	26,804
Stock-based compensation	1,005	1,135	1,138	1,162	1,176	1,354
Depreciation and amortization	7,231	7,390	6,970	7,486	7,339	7,503
Net cash from operating activities	23,536	23,410	21,194	22,791	24,266	24,530
Purchases of property and equipment	3,347	3,652	4,009	4,543	4,424	4,832
Net cash from investing activities	(20,825)	(8,683)	(12,371)	878	(18,599)	(23,588)
Share repurchases	3,221	3,456	6,035	5,054	2,432	5,953
Proceeds from long-term debt	7,431	5	2	0	6,660	9,138
Repayments of long-term debt	1,064	1,802	2,134	1,551	1,453	1,757
Net cash from financing activities	(6,120)	(14,047)	(8,871)	(15,825)	(3,132)	(5,539)
Net change in cash	(3,320)	502	(360)	7,732	2,246	(4,396)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
Johnson & Johnson	16,910	25,399	7,720*	2.4B	Q3 FY26 10-QSep 27, 2026
AbbVie	10,774	17,404	7,606*	1.8B	Q3 FY26 10-QSep 30, 2026
Abbott Laboratories	4,052	13,013	1,737*	1.7B	Q3 FY26 10-QSep 30, 2026
Merck	9,550	18,085	6,558*	2.5B	Q3 FY26 10-QSep 30, 2026
Eli Lilly	4,885	24,397	11,397*	940.7M	Q3 FY26 10-QSep 30, 2026
Amgen	13,190	10,365	4,241*	540.9M	Q3 FY26 10-QSep 30, 2026
Pfizer	1,824	16,583	5,375*	5.7B	Q3 FY26 10-QSep 27, 2026
Vertex Pharmaceuticals	4,979	3,441	643*	253.5M	Q3 FY26 10-QSep 30, 2026
Gilead Sciences	6,437	8,300	5,035*	1.2B	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 5, 2026, 9:37 PM ET. The filing on SEC.gov is the record.